PCC Rokit (PCR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
28 Aug, 2026Executive summary
Net profit for 1H2026 reached 79.3 mln PLN, an increase of 861% year-over-year, driven by improved operational results, lower financing costs, and higher results from associates.
EBITDA for 1H2026 rose by 51% to 178.9 mln PLN, with all business segments improving, especially Polyurethanes.
Revenues for 1H2026 slightly decreased by 1.4% year-over-year to 944.5 mln PLN, mainly due to a decline in Chlorine Derivatives.
The Group maintained resilience through diversified operations, broad product offerings, and a wide customer base.
Dividend of 2.65 PLN per share was paid, continuing an uninterrupted 12-year dividend history.
Financial highlights
Consolidated revenues for 1H2026: 944.5 mln PLN (down 1.4% year-over-year).
Net profit for 1H2026: 79.3 mln PLN (up from 8.2 mln PLN in 1H2025).
EBITDA for 1H2026: 178.9 mln PLN (up from 118.3 mln PLN in 1H2025).
Operating profit for 1H2026: 103.0 mln PLN (+162.8% y/y).
ROA improved to 3.3%, ROE to 5.7%, and EBITDA margin to 18.9%.
Outlook and guidance
Market volatility persists due to the Middle East conflict, impacting raw material and energy prices.
Uncertain demand recovery expected in the autumn season, especially in Polyurethanes.
Legislative changes may expand eligibility for energy compensation, potentially benefiting more installations.
The Group expects continued operational cash flow to cover investments and debt service.
External factors such as geopolitical tensions, energy prices, and regulatory changes may impact future performance.
Latest events from PCC Rokit
- Revenue and EBITDA fell sharply, with only Polyurethanes showing margin gains amid tough conditions.PCR
Q1 2026 - Net profit rose 5.6% to 40.8 million PLN despite a 6% revenue drop, aided by energy compensation.PCR
Q3 2025 - 2025 saw lower revenue and profit but higher sales volume and continued investment.PCR
Q4 2025 - H1 2025 saw sharp declines in revenue, EBITDA, and profit, but liquidity remained resilient.PCR
Q2 2025 - EBITDA and net profit fell sharply in 1-3Q 2024, driven by weak Chlorine Derivatives.PCR
Q3 2024 - Revenue and profit dropped, but liquidity and investment activity remained strong.PCR
Q2 2024 - EBITDA fell 28% and net profit 47% year-over-year, with chlorinated derivatives underperforming.PCR
Q4 2024 - EBITDA and net profit fell sharply in Q1 2025, despite higher revenue and ongoing investments.PCR
Q1 2025